Acurion provides oncologists with actionable genomic data at the biopsy stage through its OncoGaze™ platform, enabling more cancer patients to be matched with FDA‑approved precision therapies. By integrating insights from leading oncologists and top‑cited cancer researchers, the technology streamlines the decision‑making workflow and expands access to targeted treatments across multiple cancer types. OncoGaze aims to increase the proportion of patients receiving optimal, genomics‑guided care.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients do not receive FDA‑approved precision oncology therapies because molecular testing is slow, costly, and often requires additional tissue, limiting access to targeted treatments for only a small fraction of eligible cases.
Solution
Acurion’s OncoGaze™ platform delivers genomic biomarker information directly from routine H&E‑stained pathology slides at the biopsy stage. Using a proprietary deep‑learning model, the system predicts actionable biomarkers such as homologous recombination deficiency (HRD) within minutes, eliminating the need for separate genetic assays. The AI analysis runs on standard digital pathology scanners and integrates with existing clinical workflows, providing immediate, cloud‑based results that can guide therapy selection. By increasing the detection rate of HRD‑positive tumors and reducing turnaround time from weeks to minutes, OncoGaze enables oncologists to prescribe FDA‑approved targeted therapies to more patients, improving treatment outcomes.
Target Audience
Primary customers are oncology clinics, hospital pathology departments, and cancer centers seeking rapid, cost‑effective biomarker testing for solid tumors such as breast, ovarian, and pancreatic cancers.
Features
- AI‑powered analysis of standard H&E slides to predict molecular biomarkers (e.g., HRD) without additional tissue
- Deep learning model trained on thousands of annotated samples, delivering results in minutes
- Compatibility with existing digital pathology scanners and workflow integration via cloud‑based platform
- Demonstrated 1.8‑ to 3.1‑fold increase in HRD‑positive patient identification compared with conventional molecular tests
- Scalable, globally accessible solution requiring only digitized slides, reducing cost and equipment barriers
- Patent‑pending architecture with over 300 distinct claims ensuring proprietary accuracy and performance